FDA gives green signal to Luxturna for genetic blindness treatment
Date: 2017-12-20   Author: Saipriya Iyer  Category: #news

FDA gives green signal to Luxturna for genetic blindness treatment

In a major breakthrough witnessed across the healthcare sector, the U.S. Food and Drug Administration (FDA) approved Luxturna, a kind of gene therapy to treat a rare genetic eye disease caused due to gene mutation, developed by Spark Therapeutics, a pharmaceutical startup firm. As per the FDA, the treatment has received the authorization for treating patients affected due to confirmed biallelic RPE65 mutation-related retinal dystrophy, which results in the loss of vision and can lead to complete blindness. Industry analysts have claimed that Luxturna will accrue a revenue of nearly USD 78 million next year with its sales expected to rise up to USD 238 million in 2019.

Though the key officials of Spark have not unleashed the treatment charges, experts are of the view that the therapy will cost nearly USD 1 million for the patients. After the declaration of FDA’s approval of Spark’s new gene therapy, the company’s shares rose by 4% to reach USD 50.82. According to the FDA commissioner, the approval of the new therapy is the first of its kind for treating vision loss occurring due to an inherited defect in the genes. He further stated that such new discoveries in the field of biotechnology can help in curing a plethora of dreaded diseases.

Medical experts claim that Luxturna injects a functional piece of DNA in the eye cells of the adults possessing the defective gene that causes the disease leading to blindness. According to them, the therapy is not a cure, but it is aimed at halting the growth of the disease. As per authentic sources, the ICER (Institute for Clinical and Economic Review), a U.S based nonprofit entity studying the cost-effectiveness of new procedures and therapies, plans to conduct a meeting soon to examine the effectiveness of Luxturna in January next year.



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Soluble Fibers market - Demand Growth and Future Projections over 2020 – 2026
Author: Rahul Varpe

Market Overview: -

The global Soluble Fibers market was valued at USD 1.5 Billion in 2016 and is predicted to reach USD 5.5 Billion by 2025, growing at a CAGR of 16% from 2019 to 2024. Decresearch has recently published a study titled &l...


Synthetic Food market Comprehensive Analysis, Growth Forecast from 2019 to 2026
Author: Rahul Varpe

Market Overview: –

 

The global Synthetic Food market was valued at USD 9 Billion in 2018 and is projected to touch USD 12 Billion by 2025, developing at a CAGR of 4.5 % from 2019 to 2025. Decresearch declares the pu...


Food Protein Ingredient Market - Demand Growth and Future Projections over 2020 – 2025
Author: Rahul Varpe

Market Overview: –

 

The global Food Protein Ingredient market was valued at USD 17.25 Billion in 2018 and is projected to touch USD 29 Billion by 2025. Decresearch declares the publication of its latest research rep...